Skip to main content
SpringerLink
Log in

Survivin -31G/C promoter polymorphism and sporadic colorectal cancer

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Introduction

Survivin is an apoptotic inhibitor, plays an important role in cell cycle regulation, and may be involved in the development and progression of cancer. A common polymorphism at the survivin gene promoter (-31 G/C) has been shown to influence survivin expression and the risk for cancer.

Aim

The aim of the present study was to investigate whether this polymorphism could be involved in the sporadic colorectal cancer (CRC) development, prognosis, and survival.

Materials and methods

The -31G/C polymorphism of survivin promoter was analyzed by polymerase chain reaction (PCR) restriction fragment length polymorphism method in biopsies from 312 patients with sporadic CRC and 362 healthy individuals. Survivin messenger RNA (mRNA) expression in CRC tissues was detected by quantitative reverse transcriptase PCR.

Results and discussion

The genotype frequencies for -31GG, -31GC, and -31CC were 21.79%, 41.99%, and 36.22% in CRC patients and 33.98%, 45.03%, and 20.99% in healthy subjects, respectively. The frequencies of the survivin -31C allele and CC genotype were significantly higher in CRC patients than in healthy subjects (p < 0.0001). Homozygotes for the -31CC survivin genotype, expressed 1.6-fold higher mRNA levels of survivin compared to cases with the -31GG and -31GC genotypes.

Conclusion

The -31CC genotype of survivin promoter is associated with CRC and may be a risk factor for CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Thompson CB (1995) Apoptosis is the pathogenesis and treatment of disease. Science 267:1456–62

    Article  PubMed  CAS  Google Scholar 

  2. Raff M (1998) Cell suicide for beginners. Nature 396:119–22

    Article  PubMed  CAS  Google Scholar 

  3. Ambrosini G, Adida C, Alteri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–21

    Article  PubMed  CAS  Google Scholar 

  4. Deveraux QL, Reed JC (1999) IAP family proteins—suppressors of apoptosis. Genes Dev 13:239–252

    Article  PubMed  CAS  Google Scholar 

  5. Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584

    Article  PubMed  CAS  Google Scholar 

  6. Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542–547

    Article  PubMed  CAS  Google Scholar 

  7. Liston P, Fong WG, Korneluk RG (2003) The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22:8568–8580

    Article  PubMed  CAS  Google Scholar 

  8. Yamamoto T, Tanigawa N (2001) The role of surviving as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 34:207–212

    Article  PubMed  CAS  Google Scholar 

  9. Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315–5320

    PubMed  CAS  Google Scholar 

  10. Asanuma K, Moriai R, Yajima T et al (2000) Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204–1209

    PubMed  CAS  Google Scholar 

  11. Velculescu VE, Madden SL, Zhang L et al (1999) Analysis of human transcriptomes. Nat Genet 4:387–388

    Article  Google Scholar 

  12. Altieri DC, Marchisio PC, Marchisio C (1999) Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327–1333

    PubMed  CAS  Google Scholar 

  13. Xu Y, Fang F, Ludewig G et al (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527–537

    PubMed  CAS  Google Scholar 

  14. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal carcinoma. Cell 87:159–170

    Article  PubMed  CAS  Google Scholar 

  15. Sarela A, Macadam R, Farmery S, Markham A, Guillou P (2000) Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma. Gut 465:645–650

    Article  Google Scholar 

  16. Kawasaki H, Altieri DC, Lu CD et al (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071–5074

    PubMed  CAS  Google Scholar 

  17. Borbely AA, Murvai M, Szarka K et al (2007) Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60:303–306

    Article  PubMed  CAS  Google Scholar 

  18. Jang JS, Kim KM, Kang KH et al (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60:31–39

    Article  PubMed  Google Scholar 

  19. Cheng ZJ, Hu LH, Huang SJ (2008) Correlation of -31G/C polymorphisms of surviving promoter to tumorigenesis of gastric carcinoma. Ai Zheng 27:258–263

    PubMed  Google Scholar 

  20. Morson BC, Sobin LH (1976) Histologic typing of intestinal tumours: WHO technical report. WHO, Geneva

    Google Scholar 

  21. Sobin LH, Wittekind C (1997) UICC TNM classification of malignant tumours. Fifth Edition. Wiley-Liss, New York

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, School of Medicine,University of Athens, Greece, 11725, Athens, Greece

    Maria Gazouli & Nicholas P. Anagnou

  2. 2nd Propaideutic Surgical Department, Laikon University Hospital, 11725, Athens, Greece

    Nikolaos Tzanakis, Alkiviadis Kostakis & Nikolaos Nikiteas

  3. 4th Surgical Department, Attikon Hospital, University of Athens, 12462, Athens, Greece

    George Rallis

  4. 1st Department of Propaedeutic Surgery, Hippokratio Hospital, School of Medicine, University of Athens, 1527, Athens, Greece

    George Theodoropoulos

  5. St Mark’s Hospital, & Academic Institute, HA1 3UJ, Harrow, London

    Ioannis Papaconstantinou

  6. Cell and Gene Therapy Laboratory, Biomedical Research Foundation of the Academy of Athens (BRF), 11527, Athens, Greece

    Nicholas P. Anagnou

Authors
  1. Maria Gazouli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolaos Tzanakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George Rallis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Theodoropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ioannis Papaconstantinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alkiviadis Kostakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicholas P. Anagnou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nikolaos Nikiteas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikolaos Nikiteas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gazouli, M., Tzanakis, N., Rallis, G. et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24, 145–150 (2009). https://doi.org/10.1007/s00384-008-0601-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-008-0601-2

Keywords

Search

Navigation